1. Immunotherapy for Post-COVID Neuropsychiatric Symptoms: The Potential of IVIG Treatment
- Author
-
Satnarine, Travis, Ahmed, Areeg, Haq, Ayesha, Patel, Deepkumar, Gutlapalli, Sai Dheeraj, Hernandez, Grethel N., Seffah, Kofi, Zaman, Mustafa Abrar, Awais, Nimra, Khan, Safeera, Satnarine, Travis, Ahmed, Areeg, Haq, Ayesha, Patel, Deepkumar, Gutlapalli, Sai Dheeraj, Hernandez, Grethel N., Seffah, Kofi, Zaman, Mustafa Abrar, Awais, Nimra, and Khan, Safeera
- Abstract
This paper explores the neuropsychiatric consequences of SARS-CoV-2 (COVID-19) infection, specifically the use of intravenous immunoglobulin (IVIG) therapy in treating central nervous system (CNS) symptoms associated with COVID-19. The authors searched PubMed and Google Scholar using the keywords "IVIG" and "covid-19 neuropsychiatric symptoms" to find five articles, including three case reports, a retrospective study, and a prospective study, that detail the experiences of individuals with persistent neuropsychiatric symptoms after contracting COVID-19. The neuropsychiatric symptoms reported in the analyzed studies include sleep disturbance, exhaustion, cognitive decline, anxiety, and others. Common treatments for post-COVID neuropsychiatric symptoms include medications, cognitive behavioral therapy, and lifestyle modifications. IVIG therapy to manage CNS symptoms of COVID-19 has shown mixed results in studies, with some showing positive effects while others remain inconclusive. Further research is needed to understand this therapy's potential benefits and limitations fully.
- Published
- 2023